论文部分内容阅读
目的:探讨尿激酶型纤溶酶原激活剂(uPA)、纤溶酶原激活物抑制剂(PAI-1)的表达和血管形成与浸润性乳腺癌侵袭性的关系。方法:应用免疫组化SP法检测80例浸润性乳腺癌、20例良性乳腺肿瘤组织中uPA、PAI-1的表达情况并进行微血管计数。结果:uPA和PAI-1在浸润性乳腺癌组的阳性表达显著高于良性肿瘤组,且其高表达率与乳腺癌的临床病理参数密切相关(P<0.05);微血管计数在乳腺癌组和良性肿瘤组分别为30.87±7.64、20.28±8.72,两组比较有显著性差异(P<0.01)。uPA与PAI-1在浸润性乳腺癌中的表达呈正相关(P<0.05)。结论:uPA、PAI-1的高表达与浸润性乳腺癌的浸润、转移相关,uPA、PAI-1的高表达和MVD计数可作为评价浸润性乳腺癌侵袭性、评估预后和确定治疗方案的生物学指标。
Objective: To investigate the expression of urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor (PAI-1) and the relationship between angiogenesis and invasiveness of invasive breast cancer. Methods: The expression of uPA and PAI-1 in 80 cases of invasive breast cancer and 20 cases of benign breast neoplasm was detected by immunohistochemical SP method and the microvessel count was calculated. Results: The positive expression of uPA and PAI-1 in invasive breast cancer group was significantly higher than that in benign tumor group, and the high expression rate was closely related to the clinicopathological parameters of breast cancer (P <0.05) The benign tumor were 30.87 ± 7.64 and 20.28 ± 8.72 respectively, there was significant difference between the two groups (P <0.01). The expression of uPA and PAI-1 in invasive breast cancer was positively correlated (P <0.05). CONCLUSIONS: The overexpression of uPA and PAI-1 is associated with the infiltration and metastasis of invasive breast cancer. The high expression of uPA and PAI-1 and the MVD count may be used as a biomarker to evaluate invasiveness of invasive breast cancer, assess prognosis and determine treatment regimen Learning indicators.